Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
4D Molecular TherapeuticsFDMT +2.57%55 Debt-to-Equity is 0.05 as of Mar. 2026, which is at its 10-year median of 0.05. GuruFocus rates FDMT with a GF Score™ of 55/100 and a GF Value™ of $217.43 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 966 Biotechnology companies, 4D Molecular Therapeutics ranks better than 72.05% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 4D Molecular Therapeutics's Debt-to-Equity or its related term are showing as below:
FDMT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.05 Max: 0.07
Current: 0.05
During the past 9 years, the highest Debt-to-Equity Ratio of 4D Molecular Therapeutics was 0.07. The lowest was 0.02. And the median was 0.05.
FDMT's Debt-to-Equity is ranked better than 72.05% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs FDMT: 0.05
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
4D Molecular Therapeutics Debt-to-Equity Related Terms
4D Molecular Therapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FDMT vs TECX, ACHV, STTK: Debt-to-Equity Comparison
For the Biotechnology subindustry, 4D Molecular Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
4D Molecular Therapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 4D Molecular Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 4D Molecular Therapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
4D Molecular Therapeutics (FDMT) has a Debt-to-Equity of 0.05 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 4D Molecular Therapeutics and its competitors. This is near median its historical median of 0.05. Over the past decade, 4D Molecular Therapeutics' Debt-to-Equity has ranged from 0.02 to 0.07. According to the industry distribution chart, 4D Molecular Therapeutics ranks #270 out of 966 companies in the Biotechnology industry, placing it in the top 28%.
Is 4D Molecular Therapeutics' Debt-to-Equity too high?
4D Molecular Therapeutics' current Debt-to-Equity of 0.05 is near median its 10-year median of 0.05. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.07. The Biotechnology industry median Debt-to-Equity is 0.16. 4D Molecular Therapeutics' value of 0.05 is 68.8% below this industry median. Based on the distribution chart, 4D Molecular Therapeutics ranks #270 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 4D Molecular Therapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 4D Molecular Therapeutics' Debt-to-Equity compare to TECX and ACHV?
According to the Biotechnology industry distribution chart, 4D Molecular Therapeutics ranks #270 out of 966 companies for Debt-to-Equity. This puts 4D Molecular Therapeutics in the upper half of its industry. The industry median Debt-to-Equity is 0.16. 4D Molecular Therapeutics' value of 0.05 is 68.8% below this benchmark. Historically, 4D Molecular Therapeutics' own Debt-to-Equity has ranged from 0.02 to 0.07 over the past decade. While the company's 10-year median is 0.05 vs. the industry median of 0.16, 4D Molecular Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 4D Molecular Therapeutics's current Debt-to-Equity of 0.05 is 68.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 4D Molecular Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 4D Molecular Therapeutics's current Debt-to-Equity is 0.05, which is near median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 4D Molecular Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, 4D Molecular Therapeutics (FDMT) is currently considered Possible Value Trap. The stock's GF Value™ is $217.43, compared to a current price of $11.38 — trading 94.8% below its estimated fair value. The current Debt-to-Equity is 0.05, which is near median its 10-year median of 0.05 and 68.8% below the Biotechnology industry median of 0.16. 4D Molecular Therapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 4D Molecular Therapeutics (FDMT), the current Debt-to-Equity is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?
Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued.
The current stock price of $11.38 is trading 94.8% below its estimated GF Value™ of $217.43.
GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.
Key valuation signals for FDMT:
Debt-to-Equity: 0.05 (near median its 10-year median of 0.05)
GF Value™: $217.43 vs. price of $11.38 (94.8% below fair value)
Industry Position: 68.8% below the Biotechnology median (#270 of 966)
No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score
Get the complete analysis for FDMT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FDMT has been successfully added to your 
